Supernus Pharmaceuticals
SUPN
263 hedge funds and large institutions have $1.91B invested in Supernus Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 91 increasing their positions, 90 reducing their positions, and 17 closing their positions.
37,900% more call options, than puts
Call options by funds: $2.66M | Put options by funds: $7K
135% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 17
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
8% more funds holding
Funds holding: 244 → 263 (+19)
3% more capital invested
Capital invested by funds: $1.86B → $1.91B (+$48.7M)
1% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 90
0.82% less ownership
Funds ownership: 104.05% → 103.23% (-0.82%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$15.8M |
| 2 |
BlackRock
New York
|
+$13.5M |
| 3 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$9.63M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$7.82M |
| 5 |
Morgan Stanley
New York
|
+$7.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$23.9M |
| 2 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
-$12.5M |
| 3 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$10.6M |
| 4 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$9.26M |
| 5 |
AC
Armistice Capital
New York
|
-$8.24M |
SUPN Hedge Fund Activity: Q4 2022 in Review
263 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q4 2022, worth a combined $1.91B — up 2.6% from $1.86B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new SUPN positions and 17 closed out — a net gain of 23 holders — while 91 added to existing stakes and 90 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $15.8M. The largest seller was Woodline Partners, cutting an estimated $23.9M.
- 263 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q4 2022, up from 244 in Q3 2022.
- Funds reported $1.91B of Supernus Pharmaceuticals stock for Q4 2022, up 2.6% quarter-over-quarter.
- 40 funds opened new Supernus Pharmaceuticals positions in Q4 2022 and 17 closed out, a net change of +23 holders.
- The largest Supernus Pharmaceuticals buyer in Q4 2022 was Millennium Management, an estimated $15.8M added.
- The largest Supernus Pharmaceuticals seller in Q4 2022 was Woodline Partners, an estimated $23.9M sold.
Based on aggregated 13F filings for Q4 2022.